Mapp Biopharmaceutical, Inc.
We develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense.
Press Releases
BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease
BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus...
ASPR awards $110 million to advance development, procure therapeutic for Sudan ebolavirus
ASPR awards $110 million to advance development, procure therapeutic for Sudan ebolavirus The...
BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin
BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin BARDA...
Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody
Larry Zeitlin, Robert W Cross, Joan B Geisbert, Viktoriya Borisevich, Krystle N Agans, Abhishek N Prasad, Sven Enterlein, M Javad Aman, Zachary A Bornholdt, Miles B Brennan, Lioudmila Campbell, Do Kim, Neil Mlakar, Crystal L Moyer, Michael H Pauly, William Shestowsky, Kevin Whaley, Karla A Fenton, Thomas W Geisbert
Proc Natl Acad Sci USA. 2021 Mar 16;118(11):e2023332118. doi: 10.1073/pnas.2023332118.
Passive immunization with an extended half-life monoclonal antibody protects Rhesus macaques against aerosolized ricin toxin
Roy CJ, Van Slyke G, Ehrbar D, Bornholdt ZA, Brennan MB, Campbell L, Chen M, Kim D, Mlakar N, Whaley KJ, Froude JW, Torres-Velez FJ, Vitetta E, Didier PJ, Doyle-Meyers L, Zeitlin L, Mantis NJ. NPJ Vaccines. 2020 Feb 13;5:13. doi: 10.1038/s41541-020-0162-0.